Retrospective Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Sep 6, 2020; 8(17): 3774-3785
Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3774
Figure 6
Figure 6 The overall survival, progression-free survival, relapse-free survival analysis of phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 in early-stage hepatocellular carcinoma patients. A: Hepatocellular carcinoma patients with T1 stage based on the American Joint Committee on Cancer were included in the overall survival analysis, B: Progression-free survival analysis, C: Relapse-free survival analysis according to the phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 expression; D: The overall survival analysis, E: Progression-free survival analysis, and F: Relapse-free survival analysis of phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 was assessed in hepatocellular carcinoma patients with stage 1. OS: Overall survival; PFS: Progression-free survival; RFS: Relapse-free survival; AJCC-T1: T1 stage based on the American Joint Committee on Cancer; HR: Hazard ratio.